Carrying out biochemical assay for quantitatively determining efficacy of poly (ADP-ribose) polymerase inhibitor in cancer treatment, involves isolating cancer cells from cancer patients exposed or not exposed to combination treatment of DNA damaging agent and poly (ADP-ribose) polymerase inhibitor
2024-09-06
专利权人UNIV KALINGA IND TECHNOLOGY INST (UYKA-Non-standard)
申请日期2024-09-06
专利号IN202431067413-A
成果简介NOVELTY - Carrying out biochemical assay involves: (a) isolating cancer cells from cancer patients who have been exposed or not exposed to a combination treatment of a DNA damaging agent and a PARP inhibitor; (b) harvesting the isolated cancer cells; (c) preparing whole cell lysates from the harvested cells; (c) adding an assay buffer, NAD+, and fluorescent-labeled nicked DNA to the whole cell lysates, and dispensing the resulting mixture into a black 96-well plate; (d) adding an external PARP inhibitor to the mixture; and (c) measuring the fluorescent polarization of the samples using a microtiter plate reader, according to the excitation and emission wavelength of the fluorophore. USE - Method for carrying out biochemical assay for quantitatively determining the efficacy of a poly (ADP-ribose) polymerase (PARP) inhibitor in cancer treatment. ADVANTAGE - The method offers a direct and efficient way of evaluating PARP inhibitor efficacy and is suitable for high-throughput screening.
IPC 分类号C12Q-001/48 ; C12Q-001/68 ; G01N-021/64 ; G01N-033/483 ; G01N-033/574
国家印度
专业领域医药卫生
语种英语
成果类型专利
文献类型科技成果
条目标识符http://119.78.100.226:8889/handle/3KE4DYBR/15229
专题中国科学院新疆生态与地理研究所
作者单位
UNIV KALINGA IND TECHNOLOGY INST (UYKA-Non-standard)
推荐引用方式
GB/T 7714
SINHA S,BITEW S M,SETHY C,et al. Carrying out biochemical assay for quantitatively determining efficacy of poly (ADP-ribose) polymerase inhibitor in cancer treatment, involves isolating cancer cells from cancer patients exposed or not exposed to combination treatment of DNA damaging agent and poly (ADP-ribose) polymerase inhibitor. IN202431067413-A[P]. 2024.
条目包含的文件
条目无相关文件。
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。